Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and non-psychotic diagnoses

dc.contributor.authorMoreno Ruiz, María del Carmen
dc.contributor.authorMerchán Naranjo, Jessica
dc.contributor.authorÁlvarez, Mar
dc.contributor.authorBaeza, Inmaculada
dc.contributor.authorAlda, Jose A.
dc.contributor.authorMartínez Cantarero, Carmen
dc.contributor.authorParellada, Mara
dc.contributor.authorSánchez, Bernardo
dc.contributor.authorSerna, Elena de la
dc.contributor.authorGiráldez, Marisa
dc.contributor.authorArango López, Celso
dc.date.accessioned2024-12-19T10:13:23Z
dc.date.available2024-12-19T10:13:23Z
dc.date.issued2010-03-25
dc.description.abstractObjectives: Despite known metabolic effects of second-generation antipsychotics (SGAs) on children and adolescents, comparative effects in youth with different diagnoses remain underreported. We compared differences in metabolic changes three months after starting treatment with SGAs in youth with bipolar disorder and with other psychotic and nonpsychotic disorders. Methods: Weight and metabolic differences among diagnostic groups before and three months after starting treatment with SGAs were compared in a naturalistic cohort of children and adolescents (14.9 ± 3.0 years) diagnosed with bipolar disorder (n = 31), other psychotic disorders (n = 29), and other nonpsychotic disorders (n = 30), with no (35.6%) or very little (6.6 ± 9.0 days) previous exposure to antipsychotics. Composite measurements of significant weight gain [weight increase ≥ 5% at three months or increase ≥ 0.5 in body mass index (BMI) z-score] and ‘risk for adverse health outcome’ (≥ 95th BMI percentile, or ≥ 85th BMI percentile plus presence of one other obesity-related complication) were included. SGAs (risperidone, olanzapine, and quetiapine) were prescribed in comparable proportion among groups. Results: Baseline weight and metabolic indices were not significantly different among diagnoses. Three months after starting treatment with SGAs, more than 70% patients had significant weight gain, BMI z-score increased in all diagnostic groups (p < 0.001 for all comparisons), total cholesterol increased in the bipolar (p = 0.02) and psychotic (p = 0.01) disorder groups, low-density lipoprotein cholesterol increased in the bipolar group (p = 0.02), and free T4 decreased in the psychotic disorder group (p = 0.05). More patients with bipolar disorder presented overweight plus ≥ 1 obesity-related complication at follow-up. Conclusions: There are early weight gain and metabolic changes across diagnoses in youth treated with SGAs
dc.description.departmentDepto. de Medicina Legal, Psiquiatría y Patología
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.sponsorshipCentro de Investigación Biomédica en Red de Salud Mental (España)
dc.description.sponsorshipMinisterio de Ciencia e Innovación (España)
dc.description.sponsorshipInstituto de Salud Carlos III (España)
dc.description.sponsorshipFundación Alicia Koplowitz
dc.description.sponsorshipCaja Navarra
dc.description.statuspub
dc.identifier.citationMoreno C, Merchán-Naranjo J, Alvarez M, Baeza I, Alda JA, Martínez-Cantarero C, Parellada M, Sánchez B, de la Serna E, Giráldez M, Arango C. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord. 2010 Mar;12(2):172-84. doi: 10.1111/j.1399-5618.2010.00797.x
dc.identifier.doi10.1111/j.1399-5618.2010.00797.x
dc.identifier.essn1399-5618
dc.identifier.issn1398-5647
dc.identifier.officialurlhttps://doi.org/10.1111/j.1399-5618.2010.00797.x
dc.identifier.pmid20402710
dc.identifier.relatedurlhttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.1399-5618.2010.00797.x
dc.identifier.relatedurlhttps://pubmed.ncbi.nlm.nih.gov/20402710/
dc.identifier.urihttps://hdl.handle.net/20.500.14352/113020
dc.issue.number2
dc.journal.titleBipolar Disorders
dc.language.isoeng
dc.page.final184
dc.page.initial172
dc.publisherWiley
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII//FISPI040455
dc.rights.accessRightsrestricted access
dc.subject.cdu616.8
dc.subject.keywordBipolar disorder
dc.subject.keywordAntipsychotics
dc.subject.ucmPsiquiatría
dc.subject.ucmCiencias Biomédicas
dc.subject.unesco3211 Psiquiatría
dc.subject.unesco32 Ciencias Médicas
dc.titleMetabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and non-psychotic diagnoses
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number12
dspace.entity.typePublication
relation.isAuthorOfPublicationf3db4cdd-d87b-4cc1-9138-95a3454137b4
relation.isAuthorOfPublication23fb749e-1a82-4838-8fea-01d964b22093
relation.isAuthorOfPublication.latestForDiscoveryf3db4cdd-d87b-4cc1-9138-95a3454137b4

Download

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
moreno2010_BipolarDisorders_Metabolic.pdf
Size:
189.06 KB
Format:
Adobe Portable Document Format

Collections